Scholar Rock Q1 2026: A BLA on the Table, Two Factories in the Wings, and a Cash Runway That Won’t Quit
Snapshot: SRRK’s first quarter in focus
Scholar Rock (SRRK) reported a bustling but cash-burn-heavy quarter: net loss of $105.5 million for the three months ended March 31, 2026, with stock-based compensation of $18.2 million tucked into the pile. On a per-share basis, EPS came in at a negative $0.83, versus $0.67 negative per share in the year-ago period. Unsurprisingly, there was no revenue recorded in the quarter, which makes EPS comparisons heavily reliant on how the market values future development rather than current sales.
Cash, cash equivalents, and marketable securities totaled $480 million as of March 31, 2026, and the company notes an additional $100 million of debt alongside $98 million in net cash proceeds from its at-the-market (ATM) program. In other words, the burn rate is being matched by a financing runway that is designed to outlive a few regulatory cycles and a handful of clinical trial readouts.
Regulatory momentum and manufacturing milestones
The centerpiece remains apitegromab, Scholar Rock’s SMA-focused candidate. The FDA has accepted the BLA for apitegromab with a PDUFA date of September 30, 2026, meaning the clock is now running toward a potential U.S. launch decision this fall. The release confirms two fill-finish facilities—Catalent Indiana LLC (part of Novo Nordisk) and a second U.S.-based site—are part of the accepted manufacturing footprint. FDA reinspection of Catalent Indiana has completed, with facility classification expected within 90 days post-reinspection, per FDA guidelines. The second facility is on track to support commercial apitegromab supply in early Q3 2026, which aligns with the pre-launch appetite to have product readily available if approval comes through.
On the European front, EMA regulatory review is ongoing, with a Committee for Medicinal Products for Human Use (CHMP) opinion anticipated near mid-2026 for the Marketing Authorization Application. The team in Europe is actively engaging stakeholders, including SMA-focused conferences, with Europe poised for a launch in the second half of 2026, starting in Germany. This is a classic “two-seat rider on a one-up bike” moment: a U.S. launch if approved, with a broader European plan contingent on CHMP timing.
Pipeline rhythm: multiple notes on the stave
The company continues to push SRK-439, a novel, investigational subcutaneously administered myostatin inhibitor. A Phase 1 healthy volunteer study is underway, with topline data expected in the second half of 2026. Separately, the FORGE trial in FSHD (facioscapulohumeral muscular dystrophy) is targeted to initiate in mid-2026, while enrollment advances in the Phase 2 OPAL study for SMA infants and toddlers who have received certain therapies. Subcutaneous development for apitegromab is also progressing, with a Phase 1 study in healthy volunteers completed and ongoing activities expected to inform regulatory engagements after approvals.
In short, SRRK’s quarter isn’t just about the BLA; it’s about painting a broader picture where the company can move from development to commercialization across multiple programs, using a two-factory footprint as a pillar of supply strategy. This is growth-by-architecture: a regulatory moment paired with manufacturing readiness and a pipeline that can pivot as data rolls in.
Financials and liquidity: questions of runway and reliance on capital markets
With EPS at negative levels and no revenue reported, the quarter highlights a classic biotech conundrum: high burn, meaningful milestones, and a race to convert milestones into cash-efficient milestones-to-cash. Research and development expense stood at $51.8 million for the quarter, including $6.5 million in stock-based compensation. The absence of revenue underscores the need for continued access to capital markets, whether through debt facilities or equity financings, to sustain operations through anticipated regulatory milestones and potential commercial launches.
Analysts typically weigh a company’s revenue forecast and EPS consensus when judging the sustainability of a development-stage biotech’s business model. In this filing, no revenue is reported, and there’s no explicit EPS consensus disclosed. For readers tracking earnings surprise dynamics, this quarters’ results would likely register as a disappointment relative to any forward-looking revenue expectations, though the true test remains in the FDA decision and the ability to translate pipeline progress into realized revenue later in 2026.
Implications for peers and the broader SMA/myostatin space
Scholar Rock’s approach—bifurcated manufacturing capacity, early regulatory signaling, and a diversified pipeline—highlights a pattern you’ll likely see echoed among peers pursuing disease-modifying candidates with near-term regulatory catalysts. If apitegromab receives FDA clearance, the company’s two-factory setup could become a de facto standard for safety-first scale-up in niche neuromuscular indications. For sector peers, the emphasis will be on regulatory timing, supply chain resilience, and the ability to convert a robust R&D pipeline into a predictable commercial trajectory. In a market where clinical-stage companies frequently flirt with margin-free or negative earnings for years, the ability to demonstrate manufacturing readiness and a clear path to revenue will be a differentiator.
Meanwhile, the emphasis on a potential European launch remains contingent on CHMP timing, reminding investors that a single approval can still require a multi-region choreography. The emergence of SRRK’s subcutaneous SRK-439 program adds optionality for patients and payers alike, potentially broadening the addressable market if the compound proves safe and effective. If the company can bridge the gap between late-stage efficacy signals and real-world access, a handful of peers may accelerate similar strategic moves—investments in multiple facilities, parallel regulatory tracks, and patient-centric delivery options could become the new norm rather than the exception.
Bottom line: a regulatory hinge with a capital plan in its pocket
Scholar Rock is moving toward a pivotal regulatory moment with a bankroll designed to survive the wait. The EPS picture remains negative in the near term, and there is no reported earnings surprise or explicit EPS consensus in the release, but the company’s near-term catalysts—FDA decision on apitegromab’s BLA, regulatory progress in Europe, and the readiness of dual manufacturing sites—offer a plausible path to a value inflection if approvals align with the plan. The stock market will likely price this story not on today’s revenue, but on the probability of a commercial launch and the durability of funding to reach that point. For SRRK and its peers, it’s a tempo of milestones, not margins—until the day the balance sheet finally flexes its muscle.
In the near term, watch the PDUFA date, the manufacturing classifications, and any commentary on the timing of commercial launches. If the market hears a whisper that the FDA is ready to flex, SRRK’s narrative could pivot from “will we get there?” to “when do we start growing?” Until then, SRRK remains a story of science chasing scale, with the capital markets listening for every sign of traction and every data point that moves the needle on revenue forecasts and EPS consensus.